Author(s) :
Daniel Dulf1,2, Paul Kubelak1,2, Dana Iancu1, Tudor Eliade Ciuleanu1,2
1 “Ion Chiricuță” Institute of Oncology, Cluj-Napoca, Romania
2 UMF “Iuliu Hațieganu” Cluj-Napoca, Romania
Corresponding author: Tudor-Eliade Ciuleanu, Email: tudor_ciuleanu@hotmail.com
Publication History: Received - , Revised - , Accepted - , Published Online - .
Copyright: © The author(s). Published by Casa Cărții de Știință.
User License: Creative Commons Attribution – NonCommercial (CC BY-NC)
PDF
Share
Abstract
Metastatic non-small cell lung cancer has historically been associated with a poor prognosis. The introduction of targeted agents against certain molecules involved in cellular pathways has shown improved responses, but long-term survivors are still rare.
We present the case of a patient with lung adenocarcinoma harboring sensitizing EGFR mutations who showed an impressive survival of more than 9 years following a combination of systemic therapies consisting of cytotoxic drugs and EGFR TKIs that were very well tolerated.
